Introduction {#s1}
============

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the presence of Lewy bodies (LB) and Lewy neurites (LN). [@bib62] identified fibrils formed by the presynaptic protein alpha-synuclein (α-Syn, 140 residues, \~14 kD) as the main component of these human brain inclusions ([@bib63]; [@bib62]).

Certain α-Syn fibril forms can seed LB-like and LN-like inclusions in cell culture and intra-neuronal aggregation of mouse α-Syn in vivo ([@bib41]; [@bib66]; [@bib75]). In addition, abnormal α-Syn produces neuronal cell inclusions and axonal spheroids, as well as oligodendrocytic aggregates, known as glial cytoplasmic inclusions, found abundantly in Multiple System Atrophy (MSA) ([@bib4]; [@bib67]), which makes α-Syn fibrils an important target for the development of diagnostic tools and therapeutic strategies for PD and related synucleinopathies.

Despite α-Syn fibrils, other forms of α-Syn might also be involved in neurodegeneration, such as an oligomeric α-Syn intermediate ([@bib13]; [@bib36]; [@bib49]; [@bib72]; [@bib74]; [@bib79]), or the process of fibril aggregation itself ([@bib47]; [@bib57]; [@bib65]). Fibrils of α-Syn show significant fibril strain polymorphism ([@bib52]).

Several factors point to α-Syn as an important player in the onset of PD: (i) six known point mutations in the α-Syn gene (SNCA) are associated with familial forms of synucleinopathies: A30P ([@bib35]), E46K ([@bib82]), H50Q ([@bib3]), G51D ([@bib37]), A53E ([@bib51]), and A53T ([@bib54]); (ii) animal models suggest a role of α-Syn in the etiology of PD, Dementia with Lewy Bodies (DLB), and MSA ([@bib19]; [@bib26]; [@bib53]; [@bib69]); (iii) individuals with duplications or triplications of the α-Syn gene exhibit overexpression of α-Syn and develop PD ([@bib29]; [@bib61]).

Two related proteins, β-synuclein (β-Syn) and γ-synuclein (γ-Syn), with sequence homology to α-Syn, have been described ([@bib10]; [@bib31]; [@bib64]). β-Syn and α-Syn share the greatest aminoacid sequence homology, with β-Syn lacking 12 amino acids (residues 71 to 82) within the non-amyloid component region (NAC; residues 61--95 in α-Syn) ([@bib22]; [@bib70]). In synucleins, regions with the highest homologies are located in the structurally heterogeneous, amino-terminal half (residues 10--84 in α-Syn) composed of 5 to 6 imperfect repeats with the consensus sequence KTKEGV ([@bib15]). In contrast, the carboxyl terminus is highly negatively charged and unstructured ([@bib9]; [@bib73]).

A number of post-translational modifications have been described for α-Syn including phosphorylation ([@bib2]; [@bib21]; [@bib50]), acetylation ([@bib30]; [@bib43]), ubiquitination ([@bib25]), and C-terminal truncation ([@bib2]; [@bib11]). C-terminal truncation of α-Syn occurs normally in vivo, under physiological conditions and it has been shown to promote fibrillization ([@bib11]; [@bib38]; [@bib40]; [@bib76]). In turn, truncated forms of α-Syn play a role in inducing Lewy body formation ([@bib17]; [@bib38]; [@bib55]), suggesting that truncation by proteolysis may be important in the pathological process.

In vivo studies investigating α-Syn aggregation demonstrated that activation of the inflammasome and more specifically caspase-1, the enzymatic component of the inflammasome, leads to the production of an α-Syn fragment truncated at aspartic acid 121 (D121) ([@bib76]). This C-terminally-truncated α-Syn form (α-Syn(1-121)) aggregates more rapidly than full-length α-Syn (including disease-associated mutants), and its production is associated with cell toxicity. Furthermore, the use of VX-765, a pro-drug that produces a specific inhibitor of caspase-1 in vivo ([@bib77]), improved survival of a neuronal cell model of PD ([@bib76]), and reduced neurodegeneration in a transgenic mouse model of MSA ([@bib5]), suggesting an important role of α-Syn(1-121) in cellular toxicity in both, cell cultures as well as a mouse model.

To this date, high resolution structures of α-Syn fibrils are limited to the results of a micro-electron diffraction (microED) study of two small segments of the protein ([@bib59]) and a solid-state NMR structure obtained from \~5 nm diameter, single protofilaments ([@bib68]), in addition to solid state NMR studies at the secondary structure level ([@bib7]; [@bib33]; [@bib73]), and X-ray diffraction studies of shorter segments of α-Syn ([@bib39]), or α-Syn bound to other molecules ([@bib14]; [@bib24]; [@bib56]; [@bib71]; [@bib80]; [@bib81]; [@bib83]).

Here, we report the atomic structure of α-Syn(1-121) fibrils determined by cryo-electron microscopy (cryo-EM). The structure allows conclusions about the organization of α-Syn fibrils at near-atomic resolution, suggest mechanisms for fibril formation and growth, and allows conclusions on fibril stability.

Results and discussion {#s2}
======================

The 3D structure of α-Syn amyloid fibrils {#s2-1}
-----------------------------------------

Several preparations of recombinant human α-Syn fibril were screened by negative stain transmission electron microscopy (TEM; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). These included fibrils formed by full length α-Syn ([Figure 1A](#fig1){ref-type="fig"}), α-Syn phosphorylated at serine 129, N-terminally acetylated, and C-terminal truncated α-Syn comprised of residues 1--119 (α-Syn(1-119)), 1--121 (α-Syn(1-121)), or 1--122 (α-Syn(1-122)).

![Structure of α-Syn(1-121) fibril.\
(**A**) Schematic depicting the sequence of human α-Syn. The positions of the known familial mutations are indicated. β-strand regions are indicated by arrows colored from blue to red. (**B**) Cryo-EM micrograph depicting the distribution and general appearance of α-Syn fibrils. (**C**) Cryo-EM reconstruction of α-Syn(1-121) fibrils showing two protofilaments (orange and blue). (**D**) Cross-section of (**C**) illustrating the clear separation of the β-strands, also shown in [Figure 1---figure supplement 3A and B](#fig1s3){ref-type="fig"}. (**E**) Cross-section of a fibril (along the axis) illustrating the arrangement of the two protofilaments (orange and blue) and fitted atomic model. Positions of the initial (L38) and final (V95) residues fitted are indicated, as well as the initial and final residue of the NAC region (E61 to V95). Arrows indicate the location of four of the five α-Syn residues where familial mutations associated with PD occur. (**F**) Distribution of β-strands in a single protofilament of the α-Syn fibril, corresponding to residues 42 to 95. Color scheme, as in (**A**). (**G**) As in (**F**) but a perpendicular view to the fibril axis illustrating height differences in some areas of a single protofilament.](elife-36402-fig1){#fig1}

The diameters of the α-Syn fibrils produced varied from 5 nm to approximately 10 nm when studied by negative stain TEM. The fibrils formed by α-Syn(1-121) were straight, between 20 and 500 nm long and the only ones of consistent diameters of 10 nm ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). This fibrillar form α-Syn(1-121) has been described as an aggregation-prone species resulting from α-Syn truncation by caspase-1 ([@bib76]). The recombinantly produced α-Syn(1-121) used here showed a similarly aggressive aggregation profile.

Preparations of α-Syn(1-121) fibrils were quick-frozen in the holes of fenestrated carbon coated cryo-electron microscopy (cryo-EM) grids, and imaged with a Titan Krios 300kV cryo-EM instrument, equipped with a Quantum-LS energy filter and a K2 Summit direct electron detector. Helical image processing of recorded cryo-EM movies produced a 3D reconstruction of the α-Syn(1-121) fibril at an overall resolution of 3.4 Å ([Figure 1C and D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}, and [Video 1](#video1){ref-type="video"}).

![Interface region between two protofilaments of the α-Syn(1-121) fibril.\
(**A**) View along the axis of the fibril as indicated by the red rectangle on the ribbon diagram (bottom right). (**B**) (**C**) Side views of the fibril with orientations indicated by arrowheads in (**A**) and the ribbon diagram (bottom right). Panels (**B**) and (**C**) clearly illustrate the 2~1~ screw symmetry that results from the staggered arrangement of subunits.](elife-36402-fig2){#fig2}

###### Cryo-EM structure of alpha-synuclein fibril.

Details of the cryo-EM reconstruction of an alpha-synuclein fibril at 3.4 Å resolution, illustrating the interaction between two protofilaments, the 4.9 Å spacing between β-strands of a single protofilament and monomer topology in the protofilament core.

10.7554/eLife.36402.009

Our 3D map shows that fibrils are formed by two protofilaments, each of 5 nm in diameter ([Figure 1](#fig1){ref-type="fig"}). These lack C2 symmetry, but are related by an approximate 2~1~ screw symmetry, akin to the symmetry exhibited by the paired helical filaments of tau ([@bib20]) and by amyloid-ß(1-42) filaments ([@bib23]). α-Syn(1-121) fibrils are therefore polar, meaning that both protofibrils are aligned into the same direction. The position of a given ß-sheet in a protofilament is produced by the rotation of 179.5° of one sheet around its axis (helical twist), followed by a vertical translation of 2.45 Å (helical rise). This ß-sheet arrangement results in a spacing of 4.9 Å between α-Syn subunits in successive rungs of a single protofilament ([Figure 1C and D](#fig1){ref-type="fig"}). The quality of the EM map allowed an atomic model of the region between residues L38 and V95 to be built.

Each α-Syn(1-121) molecule comprises eight in-register parallel β-strands (i.e. residues 42--46 (β1), 48--49 (β2), 52--57 (β3), 59--66 (β4), 69--72 (β5), 77--82 (β6), 89--92 (β7), and 94-(\~102) (β8)), which are interrupted by glycine residues (i.e. G41 before β1, G47 between β1 and β2, G51 between β2 and β3, G67 and G68 between β4 and β5, G73 between β5 and β6, G84 and G86 between β6 and β7, and G93 between β7 and β8) or an arch (i.e. E57-K58 between β3 and β4) ([Figure 1A,F and G](#fig1){ref-type="fig"}). The β-strands β2-β7 wind around a hydrophobic intra-molecular core composed of only alanine and valine residues and one isoleucine (i.e. V48, V49, V52, A53, V55, V63, A69, V70, V71, V74, A76, V77, A78, I88, A89, A90, A91). Considering that these hydrophobic clusters are maintained along the fibril, they are likely to contribute to the stability of the protofilament. The hydrophobic core is surrounded by two hydrophilic regions (i.e. (i): Q79, T81, and (ii): T72, T75, T54, T59, and E61) both still within the core of the structure ([Figure 3](#fig3){ref-type="fig"}). While most of these side chains form so-called side chain hydrogen bond ladders ([@bib46]; [@bib58]), the second hydrophilic region comprising four threonine residues and a negatively charged glutamic acid side chain surrounds a tunnel filled with some ordered molecules of unknown nature, as evidenced by an additional density ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). The less well defined β1 and β8 strands are attached to the core, while the first 37 N-terminal residues and the last \~20 C-terminal residues of α-Syn(1-121) are not visible in the 3D reconstruction ([Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), indicating a disordered structure in line with quenched hydrogen/deuterium exchange -- solution-state NMR (H/D exchange NMR) and limited proteolysis ([@bib73]), which showed these terminal segments to be unprotected in nature. Together with our results, this suggests that approximately 40 residues of both the N- and C-terminal ends of full-length human α-Syn are flexible, and surround the structured core of the fibril with a dense mesh of disordered tails, similar to the 'fuzzy coat' recently described in the cryo-EM tau structure ([@bib20]).

![Hydrophobicity of α-Syn(1-121) fibrils.\
(**A**) Top view (fibril axis) of the hydrophobic regions (brown) in a fibril where the hydrophobic pocket at the interface between two protofilaments is evident. Hydrophobicity score from hydrophilic (−4.5, blue) to hydrophobic (4.5, brown) is indicated by the color bar. Hydrophobic residues on the outer surface of the fibril are indicated. (**B**) Close-up of the region highlighted in (**A**) indicating the hydrophobic core composed of alanines, valines and a single isoleucine (I88). Residues forming the hydrophilic region (blue) that surrounds the hydrophobic region of the core are also visible.](elife-36402-fig3){#fig3}

Two β-sheets (one from each protofilament) interact at the fibril core via a hydrophobic steric zipper-geometry comprised of β-strand β3 (i.e. residues G51-A56). As a consequence, two α-Syn molecules per fibril layer are stacked along the fibril axis ([Figure 2B and C](#fig2){ref-type="fig"}). The side chains of residues A53 and V55 form the inter-molecular surface contributing to the interface between the two protofilaments, which is further stabilized by a surface-exposed salt bridge between E57 and H50 that might be sensitive to pH, as an unprotected histidine has a pK of \~6.2 ([Figure 1---figure supplement 3H](#fig1s3){ref-type="fig"}). The same structure with a steric zipper topology was found in micro-crystals of the peptide comprising residues G47-A56 ([@bib59]). Interestingly, the β-strand β6 that is sandwiched between β-strands β2/β3 and β7 is also aligned with a neighboring molecule but shifted by one monomer along the fibril axis, as shown in [Figure 1G](#fig1){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. Thus, hetero and homo steric zippers are both present in the 3D structure. Of these, the homo steric zipper at the inter-molecular interface has an extensive and well-packed β-strand interface, forming a very densely packed fibril. This stacking generates an asymmetric fibril with two distinct ends. Furthermore, the hydrophobic core of the fibril is composed of β-strands that interact with each other in a half-stacked zipper topology, contrasting with the hydrophilic core comprised of β-strands β4 and β5, which are non-stacked ([Figure 1G](#fig1){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The latter confirms previous results from site-directed spin labeling experiments, which show that the region including residues 62--67 at the beginning of the NAC region, has a pronounced lack of stacking interactions ([@bib9]).

The outer surface of the ordered region of the fibrils is mostly hydrophilic, with a few exceptions (i.e. L38, V40, V82, A85, A90, F94, V95) ([Figure 3A](#fig3){ref-type="fig"}). The side chain of V66 should probably not be classified as surface exposed because of its interaction with β-strand β8 ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). If we ignore the influence of the non-polar alanine residues due to the small size of their side chains, the surface of the fibrils has two highly hydrophobic regions formed by residues L38 and V40, and by residues F94 and V95. Other interesting properties of the surface are the salt bridge formed by the side chains of E46 and K80 ([Figure 1---figure supplement 3G](#fig1s3){ref-type="fig"}) and the rather highly positive clustering of K43, K45, K58, H50 that requests the binding of a counter-ion, as it is supported by an observed density ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}).

The familial PD mutations in the context of the 3D fibril structure {#s2-2}
-------------------------------------------------------------------

Six familial mutations in α-Syn are known to be associated with PD and other synucleinopathies (i.e. A30P, E46K, H50Q, G51D, A53E, and A53T). Of these, all but A30P are located in the heart of the core of the fibril structure presented here ([Figure 1A and E](#fig1){ref-type="fig"}). E46 forms a salt bridge with K80 ([Figure 1---figure supplement 3G](#fig1s3){ref-type="fig"}). The mutation of the glutamic acid E46 to a positively charged lysine in an E46K mutant would thus induce a charge repulsion between β-strands β1 and β6, likely destabilizing this α-Syn fibril structure ([@bib68]). The familial PD/DLB-causing mutation E46K was found to enhance phosphorylation in mice ([@bib45]), and its toxic effect was increased by the triple-K mutation (E35K, E46K, E61K) in neuronal cells ([@bib16]).

Previous high-resolution structures of α-Syn only included small peptides or single protofilaments ([@bib59]; [@bib68]). Our 3D map suggests structural contributions of some familial mutations to fibril stability, since H50, G51 and A53 are all involved in the inter-molecular contact between the two β-sheets from adjacent protofilaments at the core of the here studied α-Syn(1-121) fibrils. Mutation of the positively charged histidine 50 into a polar, uncharged glutamine in the H50Q mutant would likely interfere with the salt bridge established between residues E57 and H50 ([Figure 1---figure supplement 3H](#fig1s3){ref-type="fig"}). Adding to the absent side-chain of glycine 51 a negatively charged aspartic acid in mutant G51D, or transforming the small side-chain of alanine A53 into a larger threonine in mutant A53T, would likely disrupt the steric zipper interaction between the two protofibrils, whereby the A53T mutation would in addition change the highly hydrophobic surface at the zipper to partly hydrophilic one. In our α-Syn(1-121) fibril structure, A53 is part of a hydrophobic pocket that defines the interaction of protofilaments and likely contributes to fibril stability as the hydrophobic interactions exist along the fibril axis. Mutations at the core of this α-Syn fibril would compromise the formation of the structure presented here. This suggests that a different fibril structure (i.e. fibril strain) could be formed from α-Syn containing the above discussed familial PD mutations.

Several features of our structure, such as non-functional hydrophobic surface patches ([Figure 3](#fig3){ref-type="fig"}), a hydrophilic tunnel ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}), and a positively charged side chain arrangement like the one comprised of residues K43, K45, K58, H50 ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}) are not found in functional amyloid structures such as that of HET-s ([@bib78]). However, similar structural characteristics have been previously observed for pathological tau filaments obtained from Alzheimer's disease brains where (i): lysine and tyrosine residues play a similarly stabilizing role in the interface region of two protofilaments of the straight filaments (SF), and (ii): the area in the center of the protofilaments is dominated by hydrophilic residues ([@bib20]). It is plausible that these structural features might arise because folding to form the amyloid fibril structure is dictated by the need to bury the maximum number of hydrophobic side-chains as efficiently as possible, as is also the case for the Aβ(1-42) amyloid fibrils ([@bib23]).

The artificial, highly toxic, but not synucleinopathy-related mutant E57K ([@bib79]) is interesting to mention in the context of the 3D structure presented, because E57 is also at the inter-molecular interface ([Figure 2](#fig2){ref-type="fig"}). The presence of a positive lysine side chain at this position in the E57K mutant would significantly interfere with the formation of the interface and even the amyloid fibril ([@bib79]). Indeed, this mutant was designed in a successful structure-based attempt to interfere with amyloid fibril formation (at least under some conditions) ([@bib79]). Furthermore, both in a lentivirus-rat system as well as in a transgenic mouse model, the E57K mutant formed a significant amount of oligomers and was highly toxic, resulting in a large decay of TH-sensitive neurons in the *substantia nigra* of rats and a motor phenotype reminiscent of PD in mice ([@bib79]). Thus, the artificial mutant E57K can be regarded as a 'familial PD-like' mutation both from the in vivo and from the structure/mechanism-based point of view.

Comparison with earlier structural data {#s2-3}
---------------------------------------

Full-length α-Syn subunits in a fibril studied by NMR (\[[@bib68]\], PDB 2N0A) were found to be in a roughly similar secondary structure arrangement as in the here reported structure of α-Syn(1-121) ([Figure 4A](#fig4){ref-type="fig"}), even though the primary structure and the side-chain interactions of our here reported structure are very different from the NMR structure. Most importantly, the fibrils used for the NMR study were only approximately 5 nm wide, which corresponds to the diameter of a single protofilament. The larger diameter of our fibrils, 10 nm, results from the interaction between two protofilaments, which allowed us to hypothesize on the nature of α-Syn(1-121) protofilament interactions. Fibrils of 5 to 10 nm in diameter found in *substantia nigra* samples from the brain of PD patients, ([@bib12]), cingulate cortex of patients with DLB ([@bib63]), cerebral cortex of PD patients ([@bib34]), and in-vitro aggregated samples ([@bib7]). [@bib12] had already suggested that the 10 nm filaments are the result of the interaction between 5 nm protofilaments.

![Comparison of α-Syn(1-121) fibrils with previous α-Syn fibril structures.\
(**A**) Overlay with the solid-state NMR structure from [@bib68] (green). Our α-Syn structure is orange in both overlays. (**B**) Overlay with the preNAC segment obtained by micro-ED by [@bib59] (purple). The red square in (**A**) indicates the area of our structure shown in (**B**). Residue 53 is mutated (i.e. A53T) in the micro-ED structure.](elife-36402-fig4){#fig4}

An important difference between our here reported structure and the NMR structure reported by [@bib68] is the orientation of residue A53. The mutation A53T is associated with early onset PD. In our structure, residue A53 faces the interface between the two protofibrils and thereby likely contributes to fibril stability. In contrast, [@bib68] reported in their NMR structure A53 to point towards the hydrophobic core of the one observed individual protofilament, which may explain the lack of 10 nm fibrils in their sample. However, it is also noted here that the NMR study by [@bib68] showed a significant disagreement among the ten lowest-energy NMR structures for residues 51--67 \[Figure 3d in [@bib68]\], indicating a lower confidence for those residues in the NMR structure. Our here reported cryo-EM map has the side-chains for those residues pointing into the opposite direction as reported in the [@bib68] structure.

Our structure includes a serine residue at position 87 ([Figure 1---figure supplement 3E](#fig1s3){ref-type="fig"}), which is one of the several phosphorylation sites in α-Syn, in addition to Y125, S129, Y133 and Y135 ([@bib48]; [@bib50]). S87 is the only phosphorylation site located within the NAC region. The previous solid-state NMR structure of α-Syn placed the side chain of this residue towards the inside of the protofilament core, leading to the assumption that phosphorylation of S87 might be the only modification occurring at a region not accessible in the fibrillar state. However, in our cryo-EM structure, S87 faces the outside of the fibril and hence remains accessible for disease-associated modification in α-Syn fibrils.

We also observed the arrangement of G47 and A78 described by [@bib68], which was proposed to favor the interaction between residues E46 and K80 and allow them to form a stable salt bridge between two consecutive α-Syn monomers ([Figure 1---figure supplement 3G](#fig1s3){ref-type="fig"}). The conservation of the geometry adopted by these residues confirms their role in facilitating backbone-backbone interactions. In addition, our structure also confirms that residues A69 and G93 (and likely G68) help to stabilize the distal loop in a protofilament ([Figure 1---figure supplement 3F](#fig1s3){ref-type="fig"}).

A microED structure obtained from crystals produced from a 10-residue peptide simulating the core of α-Syn fibrils (PreNAC, from 47 to 56; [Figure 4B](#fig4){ref-type="fig"}) and including a threonine instead of an alanine at position 53 (i.e. A53T), also proposed that residue 53 forms the hydrophobic core within a protofilament ([@bib59]). In addition, the microED model suggested that the interaction between adjacent protofilaments would occur through residues 68 to 78 (referred to as NACore) ([@bib59]). However, their short peptides did not include most residues responsible for the α-Syn monomer topology that we observed. Instead, our cryo-EM structure reveals that the PreNAC is responsible for the interaction between protofilaments, and places the NACore at the very center (i.e.the core) of a single protofilament.

Possible mechanism of fibril elongation {#s2-4}
---------------------------------------

Our 3D structure allows us to hypothesize a mechanism for fibril elongation (fibril growth). Because two different stacking modes are present (i.e. the half-stack at the intermolecular interface and the stacking of β-strand β6), the two ends of the fibrils are distinct, suggesting an end-dependent growth of the fibrils, as documented and also suggested for other amyloids ([@bib42]). One end of the fibril includes a hydrophobic cleft formed between β-strands β2/ β3 on one side and β7 on the other side (residues V49, V52, A88, I89), providing a hydrophobic entry point for the next incoming molecule, with the matching segment consisting of 5 hydrophobic residues (V74-V82, [Figure 5](#fig5){ref-type="fig"}). This suggests that the initial binding event of fibril elongation might be a hydrophobic interaction involving residues V74-V82. This peptide segment is the central part of the NAC region and strong experimental evidence suggests that it is critical for fibril formation ([@bib22]). In addition, it has been shown that β-synuclein, which lacks residues V74 to V82, is incapable of forming fibrils ([@bib22]).

![Hydrophobic cleft at the growing end of α-Syn(1-121) fibrils.\
(**A**) Views of opposite ends of α-Syn fibrils with the two protofilaments colored orange and blue. Regions corresponding to the location of the hydrophobic cleft are shown in a lighter shade. (**B**) Residues forming the hydrophobic cleft, including V49, V52, I88, A89 provide an entry point for residues V74-V82 of an incoming α-Syn molecule (atoms shown). Area shown in panel (**B**) is marked in panel (**A**) with a square.](elife-36402-fig5){#fig5}

It is intriguing to speculate that a small molecule binding into this hydrophobic cleft could be a potent fibril elongation inhibitor or tracer, with the potential to be applied in PD and other synucleinopathies. Finally, the inter-molecular stacking may also play a role in fibril elongation, since the zipper interaction is of hydrophobic nature. Furthermore, it is likely that fibril growth alternates between the two protofilament structures at the level of monomer addition. Failure thereof may result in the growth of a single protofilament with little stability, yielding a dynamic on- and off-binding of monomers and larger oligomers, which has been observed for other amyloid fibril systems ([@bib8]).

In conclusion, we present the structure of recombinant α-Syn(1-121) fibrils determined at a resolution of 3.4 Å by cryo-EM. Our structure encompasses nearly the complete protein (residues 38 to 95), and includes the NAC region (residues 61 to 95) of α-Syn. We determined that various residues associated with familial forms of PD and other synucleinopathies are located in the interacting region between two protofilaments, suggesting their involvement in fibril formation and stabilization. The cryo-EM structure presented here reveals how two protofilaments interact to form a fibril, and how the NAC region contributes to protofilament formation and stability. Our structure also presents novel insights into how several PD-relevant mutations of α-Syn would compromise the structure of this fibril, suggesting that in the case of certain familial forms of PD, a different structure of α-Syn than this fibril strain might be involved. Our findings on protofilament interaction and our hypothesis on the mechanism of fibril elongation invite for the design of molecules for diagnostics or treatment of synucleinopathies.

Materials and methods {#s3}
=====================

Recombinant proteins {#s3-1}
--------------------

Recombinant full-length α-Syn was expressed from the pRT21 expression vector in BL21(DE3) competent *Escherichia coli* (*E. coli*). For N-terminal acetylation of α-Syn, cells were pre-transfected by pNatB vector coding for the N-terminal acetylase complex (plasmid kindly provided by Daniel Mulvihill, School of Biosciences, University of Kent, Canterbury, UK) ([@bib32]). C-terminally truncated forms of α-Syn(1-119), α-Syn(1-121), and α-Syn(1-122) were expressed in BL21-DE3-pLysS competent *E. coli*. Purification of α-Syn strains was performed by periplasmic lysis, ion exchange chromatography, ammonium sulfate precipitation, and gel filtration chromatography as previously described ([@bib28]; [@bib41]). Polo like kinase 2 (PLK2) was expressed in BL21-DE3-pLysS competent *E. coli*, isolated via its His-tag and immediately used to phosphorylate purified α-Syn. This was followed by standard ion exchange and gel filtration chromatography to separate phosphorylated from non-phosphorylated α-Syn. Endotoxins were removed from all α-Syn strains by Detoxi-Gel Endotoxin Removing Gel (Thermo Scientific) usually in one run or until endotoxin levels were below detection level. The sequence of the expressed α-Syn strains was verified by tryptic digestion followed by MALDI mass spectrometry (MS) or HPLC/ESI tandem MS for total mass was performed. Purity and monodispersity was determined by Coomassie blue or Silver staining of the SDS PAGE gel and analytical ultracentrifugation and the concentration was determined by the bicinchoninic acid (BCA) assay (Thermo Scientific) with bovine serum albumin as a standard. Dialyzed and lyophilized α-Syn(1-121) was prepared by dialyzing the purified protein in a 2 kD Slide-A-Lyzer unit (Thermo Scientific, for max. 3 ml) against HPLC-water (VWR). 500 µg protein aliquots were pipetted into 1.5 ml tubes, frozen on dry ice, and lyophilized for 2 hr using an Eppendorf concentrator (Eppendorf). Lyophilized samples were stored at −80°C until use.

Fibrillization {#s3-2}
--------------

Fibrils were prepared by dissolving dialyzed and lyophilized, recombinant α-Syn protein at 5 mg/mL in incubation buffer (DPBS, Gibco; 2.66 mM KCL, 1.47 mM KH~2~PO4, 137.93 mM NaCl, 8.06 mM Na~2~HPO~4~-7H~2~O pH 7.0--7.3). Reactions of 200 µL per tube were incubated at 37°C with constant agitation (1,000 rpm) in an orbital mixer (Eppendorf). Reactions were stopped after 5 days, sonicated (5 min in a Branson 2510 water bath), aliquoted, and stored at −80°C until use. The presence of amyloid fibrils was confirmed by thioflavin T fluorimetry and high molecular weight assemblies were visualized by gel electrophoresis.

Electron microscopy {#s3-3}
-------------------

Cryo-EM grids were prepared using a Vitrobot Mark IV (ThermoFisher Scientific) with 95% humidity at 4°C. Amyloid fibrils (3 µL aliquots) were applied onto glow-discharged, 300 mesh, copper Quantifoil grids. After blotting, grids were plunge frozen in liquid ethane cooled by liquid nitrogen. Samples were imaged on a Titan Krios (ThermoFisher Scientific) transmission electron microscope, operated at 300 kV and equipped with a Gatan Quantum-LS imaging energy filter (GIF, 20 eV energy loss window; Gatan Inc.). Images were acquired on a K2 Summit electron counting direct detection camera (Gatan Inc.) in dose fractionation mode (50 frames) using the Serial EM software ([@bib44]) at a magnification of 165,000× (physical pixel size 0.831 Å) and a total dose of \~69 electrons per square angstrom (e^-^/Å^2^) for each micrograph. Micrographs were drift-corrected and dose-weighted using MotionCor2 ([@bib84]) through the Focus interface ([@bib6]). Additional data collection parameters are detailed in [Table 1](#table1){ref-type="table"}.
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###### Cryo-EM structure determination and model statistics.

  ----------------- ----------
  Data collection   
  Magnification     165000 x
  ----------------- ----------

  -------------------------------------------- -----------------------
  Pixel size (Å)                               0.831

  Defocus Range (µm)                           −0.8 to −2.5

  Voltage                                      300 kV

  Exposure time (s per frame)                  0.2

  Number of frames                             50

  Total dose (e/Å^2^)                          69 to 128

  Reconstruction                               

  Box size (pixels)                            280

  Inter-box distance (pixels)                  28

  Micrographs                                  118

  Manually picked fibrils                      792

  Initial extracted segments                   18860

  Segments after 2D classification             18371

  Segments after 3D classification             13390

  Resolution after 3D refinement (Å)           3.8

  Final resolution (Å)                         3.42

  Estimated map sharpening *B-*factor (Å^2^)   −82.6

  Helical rise (Å)                             2.45

  Helical twist (°)                            179.5

  Atomic model                                 

  Initial model used (PDB code)                2N0A

  Model resolution (Å)\                        2.94/4.08\
  FSC threshold                                FSC = 0.143/FSC = 0.5

  Model resolution range (Å)                   116.34--2.94

  Map sharpening *B*-factor (Å^2^)             −82.6

  Model composition\                           \
  Non-hydrogen atoms\                          3960\
  Protein residues\                            580\
  Ligands                                      0

  *B*-factors (Å^2^) (non-hydrogen atoms)\     \
  Protein\                                     29.85\
  Ligand                                       N.A.

  R.m.s. deviations\                           \
  Bond lengths (Å)\                            0.008\
  Bond angles (°)                              1.088

  Validation\                                  \
  MolProbity score\                            1.49\
  Clashscore\                                  1.24\
  Poor rotamers (%)                            0.00

  Ramachandran plot\                           \
  Favored (%)\                                 85.71\
  Allowed (%)\                                 14.29\
  Disallowed (%)                               0.00
  -------------------------------------------- -----------------------

Image processing {#s3-4}
----------------

Helical reconstruction was carried out with the RELION 2.1 software ([@bib60]), using methods described in [@bib27]. Filaments were manually selected using the helix picker in RELION 2.1. Filament segments were extracted using a box size of 280 pixels (233 Å) and an inter-box distance of 28 pixels. A total of 18,860 segments were extracted from 792 fibrils manually picked from 118 micrographs ([Table 1](#table1){ref-type="table"}). 2D classification was carried out with a regularization value of T = 10, and 2D class averages with a clear separation of β-strands were selected for further data processing. Power spectra of 2D class averages show the layer line at 1/ (4.9 Å) with peak intensities on both sides of the meridian (Bessel order n = 1). This is the result of an approximate 2~1~ screw symmetry between α-Syn subunits on the two protofilaments ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Segments assigned to the best 2D classes were used for 3D classification using a regularization value of T = 8 and with optimization of the helical twist and rise. For both 3D classification and refinement, a *helical_z\_percentage* parameter of 10% was used, which defines the size of the central part of the intermediate asymmetrical reconstruction that is used to apply real-space helical symmetry ([@bib27]). An initial reconstruction was calculated using a cylinder generated via the helix toolbox in RELION 2.1 as initial model. This reconstruction was low-pass filtered to 60 Å and employed as the initial model for a 3D classification with a single class (K = 1) and T = 20, an approach that allowed the successful reconstruction of amyloid filaments ([@bib20]). The handedness of the reconstruction was determined by comparison with atomic force microscopy images, which showed left-coiled surface patterns for the fibrils.

Refinement was carried out by the auto-refine procedure with optimization of helical twist and rise. This resulted in a structure with overall resolution of 3.8 Å. Post-processing with a soft-edge mask and an estimated map sharpening *B*-factor of −82.6 Å gave a map with a resolution of 3.4 Å (by the FSC 0.143 criterion). An estimation of local resolution was obtained using RELION 2.1 and a local-resolution-filtered map was calculated for model building and refinement.

Model building and refinement {#s3-5}
-----------------------------

A model of the α-Syn(1-121) fibril was built into the Relion local resolution-filtered map using COOT ([@bib18]), with the PDB ID 2N0A as an initial model for the early interpretation of the map. The structure helped to determine the directionality of the protein chain and facilitated the assignment of densities in the map to specific residues. However, due to the large differences between the NMR structure and our EM map, major rebuilding was necessary. The high quality of the EM map allowed us to unambiguously build residues 38--95. A comparison was also carried out between our structure and X-ray structures of α-Syn fragments 69--77 (PDB ID 4RIK), 68--78 (PDB ID 4RIL) and 47--56 (PDB ID 4ZNN; with the mutation A53T).

The structure (10 monomers, 5 on each protofilament) was refined against the RELION local resolution-filtered map with PHENIX real space refine ([@bib1]). Rotamer, Ramachandran restraints, and 'NCS' constraints were imposed, and two *B*-factors per residue were used during refinement. For validation, we randomized the coordinates (with a mean shift of 0.3 Å) and refined (using the same settings) against one of the refinement half-maps (half-map 1). We then calculated the FSC between that model (after refinement against half-map 1) and half-map 1, as well as the FSC between the same model and half-map 2 (against which it was not refined). The lack of large discrepancies between both FSC curves indicates no overfitting took place.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Cryo-EM structure of alphα-Synuclein fibrils\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Sjors HW Scheres as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by John Kuriyan as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Marcus Fändrich (Reviewer \#2); Dennis J Selkoe (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this study, Guerrero-Ferreira and collaborators use helical reconstruction cryo-electron microscopy to report a near-atomic resolution structure of an α-synuclein (α-Syn) fibril. Unlike previous high-resolution structures of α-synuclein fibrils obtained with solid-state NMR and micro-ED, cryo-EM allowed the determination of an arrangement where two protofilaments form a polar fibril composed of β-strands. Interestingly, a region associated with mutations that predispose to familial forms of Parkinson\'s disease is in the interface between the two protofilaments, where the mutants could influence the formation and stability of fibrils.

Overall, this study is experimentally sound and provides further evidence of the power of cryo-EM to elucidate the structures of amyloid-like fibrils made from recombinant proteins in vitro. However, all three reviewers agreed that the current manuscript would need a very careful and major revision before being suitable for publication in *eLife*. Besides adequately addressing the important conceptual points outlined by the three reviewers below, the manuscript should also be subjected to an extensive rewrite as the language used is often unclear and imprecise.

There is some overlap between point 2 by reviewer \#3 and the paragraph with the request for additional evidence of seeding by reviewer \#1. After deliberation among the reviewers it was agreed that it would probably be hard to find convincing arguments for the pathophysiological relevance of the solved fibrils at this point. Therefore, the revision should at least address the comments made by reviewer \#3, i.e. to better explain the choice made for the 1-121 mutant.

*Reviewer \#1:*

This manuscript describes a 3.4Å cryo-EM structure of in vitro aggregated α-synuclein fibrils (from a construct comprising residues 1-121). The authors built a near-atomic model of the α-synuclein fibril, which contains two protofilaments with a helical pseudo-two-fold screw symmetry. Each protofilament comprises eight parallel β-strands, forming a hydrophobic core with disordered random-coil-like tails on both ends. The authors describe the position of several familial Parkinson\'s disease (PD) mutations in the context of the 3D fibril structure, interpreting that the mutations would compromise the formation of the fibril structure presented here. The structure shares a similar topology with an NMR structure of in-vitro aggregated full-length α-synuclein fibrils that form single protofilaments. The manuscript also proposes a possible mechanism of fibril growth based on the observation of a hydrophobic cleft on one side of the fibril, which would then also be a potential target for fibril growth inhibitors or tracer compounds.

Although the structure presented is interesting and could in principle be worthy of publication in *eLife*, the current manuscript is written very poorly. Moreover, there is no additional data to back up some of the claims made based on the structure. Therefore, this paper will need a very major revision before it will be suitable for publication.

The Introduction is very short, and does not do credit to the large body of literature existing on α-synuclein.

Being the result of an in-vitro aggregation experiment, the relevance of the structures in disease is questionable. This is further exacerbated by using a truncation construct instead of the wildtype protein. It is not entirely clear from Figure 1---figure supplement 1 why the authors did not actually perform structure determination of the wildtype protein. Because of this change, the experiments performed on wildtype protein before by others may not be relevant for this structure. Therefore, the authors should provide evidence that the fibrils they used can still seed aggregation in cell cultures or mouse models.

Subsection "The familial PD mutations in the context of the 3D fibril structure", end of second paragraph: I cannot see how the observation that familial PD mutations lie at the interface between the protofilaments would suggest that this fibril has some sort of \'native function\'. Then, that exact statement is refuted in the next line, where evolution towards a fibril with a hydrophobic patches is deemed unlikely. This second statement is also strange. Why would there be an evolutionary pressure to form fibrils in the first place, regardless of their hydrophobicity? And more importantly, what do the authors themselves think is the relevance of this structure?

The authors discuss differences with the solid-state NMR structure by Tuttle et al. It could be that the filaments are indeed different, but it is perhaps equally likely that the ssNMR model is wrong, as not enough restraints may have been acquired to define a unique structure. Therefore, it would be interesting to know whether the cryo-EM structure actually explains the NMR data, or whether some distances measured by NMR are incompatible with the cryoEM structure, and the two are indeed different. This possibility should at least be discussed.

Subsection "Possible mechanism of fibril growth", first sentence: Now the fibrils are called \'the transmissible species\' solely based on some similarities with the NMR structure (which is in fact rather different and comprises only a single protofilament). This is at least confusing, as previously it was suggested this fibril structure is different from the one relevant to PD.

The authors hypothesize a mechanism for fibril growth based on the observation of a cleft on one side of the fibril. Although interesting in principle, they refer to their \'findings on the mechanism of fibril elongation\'. However, they present no additional data that actually provides proof of a single \'growing end\' of the fibril, nor its directionality.

*Reviewer \#2:*

The study is well done. However, it contains a rather serious error in the β-sheet nomenclature, and it requires some further clarifications regarding the analysis before publication can be recommended.

1\) There is a misclassification of the β-sheet structure, which does *not* possess a Greek key topology. Richardson defined a Greek key as a (+3) -1 -1 (+3) topology of 5 hydrogen bonded strands from the SAME β-sheet, with the exception that the first or the last strand can be missing. In the present case, however, the strands belong to β-sheets that are clearly different, and the strands do not interact with one another through backbone hydrogen bonds but rather via their side chains. Unfortunately, this misclassification was introduced previously to the amyloid field by another paper, but it is now important that we now avoid an error propagation. The term Greek key is misleading in the present context and needs to be deleted.

2\) Which features in the original cryo-EM images show that the fibril possesses a screw axis? Please clarify through a new figure in the supplementary information.

3\) The manuscript currently does not describe well how the obtained 3D density corresponds to the original experimental data? This should also merit a figure.

4\) Please present evidence that the model is an adequate description of the 3D map or original cryo-EM data, for example, by comparing class averages with 2D projections of the density or by comparisons of the power spectra obtained with class averages, 3D maps and models.

*Reviewer \#3:*

In this study, Guerrero-Ferreira and collaborators use helical reconstruction cryo-electron microscopy to report a near-atomic resolution structure of an α-synuclein (α-Syn) fibril. Unlike previous high-resolution structures of α-synuclein fibrils obtained with solid-state NMR and micro-ED, cryo-EM allowed the determination of an arrangement where two protofilaments form a polar fibril composed of β-strands. Interestingly, a region associated with mutations that predispose to familial forms of Parkinson\'s disease is in the interface between the two protofilaments, where the mutants could influence the formation and stability of fibrils.

Overall, this study is experimentally sound, well-illustrated and provides further evidence of the power of cryo-EM to elucidate the structures of amyloid-like fibrils made from recombinant proteins in vitro.

While the structural data appear to be appropriately analyzed and illustrated, I will allow structural biologists to comment on the details of the analysis of the cryoEM images of the 2-protofilament, 10 nm fibril solved here. Regardless of the interpretation of the molecular details of this 3D fibril structure, there are some major conceptual issues (numbered below) about their report that the authors should address in order to support the relevance of this aa1-121 fibril generated in vitro to the normal in vivo biology of α-Syn and the role of α-Syn fibrils in human synucleinopathies, particularly PD.

1\) Already in the Abstract and Introduction, the authors should explain to readers whether they view the fibrils they elegantly analyze by cryoEM as modeling normal or pathological assembles. This is not really made clear until a rather speculative discussion where they write (somewhat ambiguously) \"this suggests that this fibril structure might have a native function, and that a different fibril structure could be involved in the toxicity of the disease\". Then, in the next sentence, they state an apparently contradictory opinion: \"it seems likely that the fibril structure presented here doesn\'t have a native or mechanistic function by itself\", and shortly thereafter, they state that \"similar, rather unique \[meaning?\] structural characteristics have been previously observed for tau\". Are those tau structures believed by those respective authors and also by the current authors to be normal or pathological? It is widely assumed in the neurodegenerative field that α-Syn and tau are normally soluble and functional proteins in neurons, and that amyloid-like fibrils or protofilaments do not occur normally and are pathological. But in the Results and Discussion, and elsewhere in the manuscript, the authors seem unclear about the precise disease-relevance of this wild-type α-Syn fibril. An example of this ambiguity is the sentence: \"The here presented structure therefore hints at the possibility that a different structure or mechanism might be the causative agent for PD, at least for familial PD\". This sentence sounds vague, and the term \"causative agent for PD\" seems overreaching. Such statements may be confusing to α-Syn biologists trying to interpret the meaning and impact of this structural work.

2\) At the beginning of Results, the authors show Ems of \"several preparations of recombinant human α-Syn fibril\", including those formed by full-length (FL) unmodified α-Syn and N-terminally acetylated α-Syn. They then say that \"the fibrils formed by α-Syn(1-121) were straight, between 20 and 500 nm long and the only ones consistently 10 nm in diameter\". They conclude \"for this reason, α-Syn(1-121) was used to proceed with structural analysis by cryo-EM\" For what reason? Why do these in vitro characteristics justify choosing the α-Syn(1-121) variant to focus their work on? This seems arbitrary or at least not well justified. The authors should explain this and further state why an N-acetylated FL α-Syn (filaments of which are nicely shown by EM in Figure 1C) would not have been more biologically relevant, since the vast majority of α-Syn in human neurons is in this state, both in healthy people and in PD subjects. An example of this concern arises in the first paragraph of the subsection "Comparison with earlier structural data", where the authors contrast their new structure of α-Syn(1-121) to that of Tuttle et al. of a ssNMR structure of a pathogenic fibril of FL α-Syn; this contrast raises the question of why the authors\' α-Syn(121) fibril is a more biologically relevant structure.

3\) The authors state already in the Abstract and in several places throughout the paper that human PD has as a major feature the cell-to-cell propagation of α-Syn. While this is a popular and much studied hypothesis, there is no direct evidence to date that physical passage of α-Syn between neurons occurs -- and is required for -- in the human disease, i.e., occurs in patients with PD and DLB. This is especially true as regards fully formed amyloid-like fibrils of α-Syn, despite the authors\' claim that \"the fibril species presented here is likely to be the transmissible species.\" Even those championing the pathogenic spread hypothesis do not claim that fully formed, 10 nm fibrils such as are examined here are the likely form of α-Syn that spreads from neuron to neuron. More readily diffusible soluble oligomers of α-Syn are more likely to be candidates for inter-neuronal passage. The authors would be wise to reserve their speculations about this to the end of their paper, assuming they believe that neuron-to-neuron transport of the 10 nm fibrils they characterize will turn out be biologically true in PD patients, rather than assuming this outcome already in the second sentence of the Abstract and in the Introduction (third paragraph). The authors should also clarify for readers that their statement \"our 3D structure reveals some detailed insight into the mechanism of fibril replication\" is distinct from the mechanisms of any fibril propagation or \"transmissibility\", which they mention just 3 lines earlier. These terms (\"replication\" and \"transmissibility\") should not be conflated in the reader\'s mind.

4\) A related question of biological interpretation and PD-relevance is whether the authors assume the 10 nm amyloid-type fibrils they define would occur intra- or extracellularly. If intraneuronal, do they then believe their fibrils are similar to the α-Syn filaments that accumulate in Lewy bodies and neurites? In this context, the authors emphasize that their fibrils are of wild-type α-Syn and that PD-causing mutations (e.g., H50Q, G51D, A53E, A53T) would each alter \"the inter-molecular contact between two β-sheets from adjacent protofilaments at the core of the fibrils\" they study, including the disruption of the stearic zipper interaction they postulate on the basis of their 3D structure. So, while an additional structure determination of an α-Syn mutant is probably beyond the scope of this study, it would be very interesting to at least have a rough a priori reconstruction of any of the fPD mutants occurring at the interface between the protofilaments -- especially in light of their strong claims about the importance of this interface. Would the authors expect to observe a radically different structure?

5\) The advance of Fitzpatrick and collaborators\' determination of the structure of tau filaments derives from the fact that the material came from human patients. Would the authors expect fibrils within Lewy bodies in patients suffering from synucleinopathies to maintain the same overall structure they report here?

6\) Compelling ssNMR data suggest the existence of only minor structural differences between wt α-synuclein and the A53T mutant. How would this affect the authors\' assumption that the mutations are clustered at the core of the interacting protofilaments and therefore have major effects on the structure of the wt fibrils prepared here?

7\) The α-synuclein fibril diameter reported by some labs within Lewy bodies is \~5 nm, akin to a single protofilament of the current structure. How do the authors justify the importance of a two-protofilament fibril made here from bacterially expressed, non-acetylated recombinant α-Syn?

8\) Any comment on why the authors find that α-Syn(1-119) is unable to form fibrils (Figure 1D), despite the fact that the C-terminal residues remain dynamic even in the fibrillar state?

10.7554/eLife.36402.022

Author response

> Reviewer \#1:
>
> \[...\] Although the structure presented is interesting and could in principle be worthy of publication in eLife, the current manuscript is written very poorly. Moreover, there is no additional data to back up some of the claims made based on the structure. Therefore, this paper will need a very major revision before it will be suitable for publication.
>
> The Introduction is very short, and does not do credit to the large body of literature existing on α-synuclein.

The introduction has been extended to include a larger review of the existing α-synuclein literature.

> Being the result of an in-vitro aggregation experiment, the relevance of the structures in disease is questionable. This is further exacerbated by using a truncation construct instead of the wildtype protein. It is not entirely clear from Figure 1---figure supplement 1 why the authors did not actually perform structure determination of the wildtype protein. Because of this change, the experiments performed on wildtype protein before by others may not be relevant for this structure. Therefore, the authors should provide evidence that the fibrils they used can still seed aggregation in cell cultures or mouse models.

In order to highlight the importance of this fibril form (α-Syn 1-121) and explain why it was selected for cryo-EM structure determination, we have added references to published work on the α-Syn 1-121 fibrils. Previous in vivo experiments with a neuronal Parkinson's Disease cell model as well as a mouse model of Multiple System Atrophy showed the aggregation propensity of α-Syn 1-121, as well as its association with neuronal cell toxicity. A recombinant α-Syn 1-121 has previously been investigated as well and exhibited the same aggregation profile. This is now detailed in the manuscript.

Relevant references are listed in the manuscript. These include: Bassil et al., 2016; Wang et al., 2016.

> Subsection "The familial PD mutations in the context of the 3D fibril structure", end of second paragraph: I cannot see how the observation that familial PD mutations lie at the interface between the protofilaments would suggest that this fibril has some sort of \'native function\'. Then, that exact statement is refuted in the next line, where evolution towards a fibril with a hydrophobic patches is deemed unlikely. This second statement is also strange. Why would there be an evolutionary pressure to form fibrils in the first place, regardless of their hydrophobicity? And more importantly, what do the authors themselves think is the relevance of this structure?

A description of the relevance of this structure has been added to the Results and Discussion section of the manuscript. In addition, the above-mentioned claims have been removed. The Discussion was extended and corrected.

> The authors discuss differences with the solid-state NMR structure by Tuttle et al. It could be that the filaments are indeed different, but it is perhaps equally likely that the ssNMR model is wrong, as not enough restraints may have been acquired to define a unique structure. Therefore, it would be interesting to know whether the cryo-EM structure actually explains the NMR data, or whether some distances measured by NMR are incompatible with the cryoEM structure, and the two are indeed different. This possibility should at least be discussed.

We have now re-written the discussion of the NMR structure. We highlight the similarities (general fold) and the differences (single protofibril in NMR, double fibril in our map) The NMR structure had a significantly higher discrepancy between lowest-energy structures for residues 51-67 (Tuttle et al., Figure 3D), and exactly for these residues, our map has the side chains pointing into the opposite direction than in the NMR structure. We indicate this in the revised manuscript.

> Subsection "Possible mechanism of fibril growth", first sentence: Now the fibrils are called \'the transmissible species\' solely based on some similarities with the NMR structure (which is in fact rather different and comprises only a single protofilament). This is at least confusing, as previously it was suggested this fibril structure is different from the one relevant to PD.

We agree with the reviewer. As cell-to-cell propagation of fibrils was not the scope of our study, the parts of the text referring to neuron-to-neuro transfer of α-Syn fibrils have now been removed.

> The authors hypothesize a mechanism for fibril growth based on the observation of a cleft on one side of the fibril. Although interesting in principle, they refer to their \'findings on the mechanism of fibril elongation\'. However, they present no additional data that actually provides proof of a single \'growing end\' of the fibril, nor its directionality.

The text referring to the mechanism of fibril elongation was modified as suggested and is now clearly stated as a hypothesis.

> Reviewer \#2:
>
> The study is well done. However, it contains a rather serious error in the β-sheet nomenclature, and it requires some further clarifications regarding the analysis before publication can be recommended.
>
> 1\) There is a misclassification of the β-sheet structure, which does not possess a Greek key topology. Richardson defined a Greek key as a (+3) -1 -1 (+3) topology of 5 hydrogen bonded strands from the SAME β-sheet, with the exception that the first or the last strand can be missing. In the present case, however, the strands belong to β-sheets that are clearly different, and the strands do not interact with one another through backbone hydrogen bonds but rather via their side chains. Unfortunately, this misclassification was introduced previously to the amyloid field by another paper, but it is now important that we now avoid an error propagation. The term Greek key is misleading in the present context and needs to be deleted.

We thank the reviewer for the clarification of the terminology. As suggested, the term Greek key has been removed from the text.

> 2\) Which features in the original cryo-EM images show that the fibril possesses a screw axis? Please clarify through a new figure in the supplementary information.

Additional panels were added to Figure 1---figure supplement 2 with 2D class averages and power spectra showing no meridional intensities on the 1/(4.9 Å) layer line with results from an approximate 2~1~ screw axis. An explanation was also added to the Image Processing section of the Materials and methods.

> 3\) The manuscript currently does not describe well how the obtained 3D density corresponds to the original experimental data? This should also merit a figure.

Additional panels were added to Figure 1---figure supplement 2 to compare class averages with 2D projections of the 3D map.

> 4\) Please present evidence that the model is an adequate description of the 3D map or original cryo-EM data, for example, by comparing class averages with 2D projections of the density or by comparisons of the power spectra obtained with class averages, 3D maps and models.

Additional panels were added to Figure 1---figure supplement 2 to compare class averages with 2D projections of the 3D map and the model as suggested. Power spectra for all sets of images were also included. The figure legend was modified accordingly.

> Reviewer \#3:
>
> \[...\] 1) Already in the Abstract and Introduction, the authors should explain to readers whether they view the fibrils they elegantly analyze by cryoEM as modeling normal or pathological assembles. This is not really made clear until a rather speculative discussion where they write (somewhat ambiguously) \"this suggests that this fibril structure might have a native function, and that a different fibril structure could be involved in the toxicity of the disease\". Then, in the next sentence, they state an apparently contradictory opinion: \"it seems likely that the fibril structure presented here doesn\'t have a native or mechanistic function by itself\", and shortly thereafter, they state that \"similar, rather unique \[meaning?\] structural characteristics have been previously observed for tau\". Are those tau structures believed by those respective authors and also by the current authors to be normal or pathological? It is widely assumed in the neurodegenerative field that α-Syn and tau are normally soluble and functional proteins in neurons, and that amyloid-like fibrils or protofilaments do not occur normally and are pathological. But in the Results and Discussion, and elsewhere in the manuscript, the authors seem unclear about the precise disease-relevance of this wild-type α-Syn fibril. An example of this ambiguity is the sentence: \"The here presented structure therefore hints at the possibility that a different structure or mechanism might be the causative agent for PD, at least for familial PD\". This sentence sounds vague, and the term \"causative agent for PD\" seems overreaching. Such statements may be confusing to α-Syn biologists trying to interpret the meaning and impact of this structural work.

We are thankful for these observations, which allowed us to improve our Discussion.

The relevance of the solved structure has been explained in the Results and Discussion section of the manuscript. In addition, the Discussion has been corrected to better explain our points of view and clarify several sentences and the impact of our work.

> 2\) At the beginning of Results, the authors show Ems of \"several preparations of recombinant human α-Syn fibril\", including those formed by full-length (FL) unmodified α-Syn and N-terminally acetylated α-Syn. They then say that \"the fibrils formed by α-Syn(1-121) were straight, between 20 and 500 nm long and the only ones consistently 10 nm in diameter\". They conclude \"for this reason, α-Syn(1-121) was used to proceed with structural analysis by cryo-EM\" For what reason? Why do these in vitro characteristics justify choosing the α-Syn(1-121) variant to focus their work on? This seems arbitrary or at least not well justified. The authors should explain this and further state why an N-acetylated FL α-Syn (filaments of which are nicely shown by EM in Figure 1C) would not have been more biologically relevant, since the vast majority of α-Syn in human neurons is in this state, both in healthy people and in PD subjects. An example of this concern arises in the first paragraph of the subsection "Comparison with earlier structural data", where the authors contrast their new structure of α-Syn(1-121) to that of Tuttle et al. of a ssNMR structure of a pathogenic fibril of FL α-Syn; this contrast raises the question of why the authors\' α-Syn(121) fibril is a more biologically relevant structure.

In order to highlight the importance of this fibril form (α-Syn 1-121) and extend on the reasons why it was picked for cryo-EM analysis, we have added text citing previous research concerning the α-Syn(1-121) truncation. in vivo experiments on a neuronal Parkinson's Disease cell model as well as a mouse model of Multiple System Atrophy have demonstrated the aggregation propensity of this α-Syn species as well as its association with neuronal cell toxicity. We also explain that α-Syn(1-121) was the most suitable sample for a high-resolution structure analysis, due to the constant diameters and straight fibril structure.

> 3\) The authors state already in the Abstract and in several places throughout the paper that human PD has as a major feature the cell-to-cell propagation of α-Syn. While this is a popular and much studied hypothesis, there is no direct evidence to date that physical passage of α-Syn between neurons occurs -- and is required for -- in the human disease, i.e., occurs in patients with PD and DLB. This is especially true as regards fully formed amyloid-like fibrils of α-Syn, despite the authors\' claim that \"the fibril species presented here is likely to be the transmissible species.\" Even those championing the pathogenic spread hypothesis do not claim that fully formed, 10 nm fibrils such as are examined here are the likely form of α-Syn that spreads from neuron to neuron. More readily diffusible soluble oligomers of α-Syn are more likely to be candidates for inter-neuronal passage. The authors would be wise to reserve their speculations about this to the end of their paper, assuming they believe that neuron-to-neuron transport of the 10 nm fibrils they characterize will turn out be biologically true in PD patients, rather than assuming this outcome already in the second sentence of the Abstract and in the Introduction (third paragraph).

We agree with the reviewer that mention of transmissibility of α-Syn fibrils may prove confusing. Determination of fibril cell-to-cell propagation was out of the scope of our study. Therefore, parts of the text referring to neuron-to-neuro transfer of α-Syn fibrils have been removed.

> The authors should also clarify for readers that their statement \"our 3D structure reveals some detailed insight into the mechanism of fibril replication\" is distinct from the mechanisms of any fibril propagation or \"transmissibility\", which they mention just 3 lines earlier. These terms (\"replication\" and \"transmissibility\") should not be conflated in the reader\'s mind.

The term "transmissibility" has been removed from this section for clarity. We describe our proposed hypothesis on the mechanism of fibril elongation.

> 4\) A related question of biological interpretation and PD-relevance is whether the authors assume the 10 nm amyloid-type fibrils they define would occur intra- or extracellularly. If intraneuronal, do they then believe their fibrils are similar to the α-Syn filaments that accumulate in Lewy bodies and neurites? In this context, the authors emphasize that their fibrils are of wild-type α-Syn and that PD-causing mutations (e.g., H50Q, G51D, A53E, A53T) would each alter \"the inter-molecular contact between two β-sheets from adjacent protofilaments at the core of the fibrils\" they study, including the disruption of the stearic zipper interaction they postulate on the basis of their 3D structure. So, while an additional structure determination of an α-Syn mutant is probably beyond the scope of this study, it would be very interesting to at least have a rough a priori reconstruction of any of the fPD mutants occurring at the interface between the protofilaments -- especially in light of their strong claims about the importance of this interface. Would the authors expect to observe a radically different structure?

We appreciate the comment from this reviewer regarding the fibril structure of α-Syn with PD-causing mutations, and we do share the interest in solving such structures. However, structure determination of mutant α-Syn fibrils is likely a more difficult and long process, which we are afraid is beyond the scope of this study.

> 5\) The advance of Fitzpatrick and collaborators\' determination of the structure of tau filaments derives from the fact that the material came from human patients. Would the authors expect fibrils within Lewy bodies in patients suffering from synucleinopathies to maintain the same overall structure they report here?

Lewy bodies contain a high concentration of α-Syn. To our knowledge, purification of α-Syn fibrils from human brain so far requires rather harsh conditions (e.g., solubilization with sarcosine at elevated temperatures for several hours under stirring), and so far has not resulted in fibril material of sufficient quality for structural analysis. The fact that our here presented α-Syn fibril structure appears to be incompatible with certain familial PD α-Syn mutations, suggests that at least in some PD patients affected by those mutations, the here presented fibril structure should not be able to form.

> 6\) Compelling ssNMR data suggest the existence of only minor structural differences between wt α-synuclein and the A53T mutant. How would this affect the authors\' assumption that the mutations are clustered at the core of the interacting protofilaments and therefore have major effects on the structure of the wt fibrils prepared here?

α-Syn is known to form fibrils of different strain types (e.g., Peelaerts et al., 2015). Lemkau et al. (PLOS One, 2013) saw only local differences around residue 53 between wt and A53T fibrils. At this point, we cannot explain their findings, which were obtained by seeding and longer incubation times.

> 7\) The α-synuclein fibril diameter reported by some labs within Lewy bodies is \~5 nm, akin to a single protofilament of the current structure. How do the authors justify the importance of a two-protofilament fibril made here from bacterially expressed, non-acetylated recombinant α-Syn?

There are reports of 10 nm fibers extracted from Lewy bodies (Crowther, Daniel, and Goedert, Neuroscience Letters (2000)). In their research, filaments were isolated from pooled substantia nigrae of 10 PD cases. Their research also suggests that the 10 nm filaments may contain 5 nm protofilaments as substructures.

A discussion of various instances where 5 and 10 nm fibrils have been found in brain of PD patients has been added as part of the Results and Discussion section for clarification.

> 8\) Any comment on why the authors find that α-Syn(1-119) is unable to form fibrils (Figure 1D), despite the fact that the C-terminal residues remain dynamic even in the fibrillar state?

In our hands, the construct α-Syn(1-119) did not, or only form very short fibrils. We cannot explain this behavior. It may have something to do with shielding of fibril surface areas by the longer N- and C-termini.

[^1]: Structural Biology of Molecular Machines Group, Protein Structure and Function Programme, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
